Braveheart Bio, Inc.: Stifel initiates coverage with Buy rating; target price $45
BRVE•Related News
UBS names John Houlihan South Market executive
UBS•
Utah Medical Products unit Femcare buys UK’s Orion Medical Supplies for £3.6 million
UTMD•
Ensysce completes enrollment in final stage of PF614-MPAR-102 overdose-protection opioid study
ENSC•
Lexicon post hoc SOLOIST-WHF analysis shows sotagliflozin benefit holds across baseline blood pressure levels
LXRX•
California utilities slide after wildfire bill amendments, broker downgrades
PCG•